Novozymes’ biosolutions to be considered as part of Amager Resource Center’s (ARC) carbon capture project

Novozymes biosolutions to be tested as part of ARC’s official application to the European Union’s Innovation Fund to build a carbon capture facility at ARC’s waste-to-energy plant in Copenhagen, Denmark.

copenhill waste-to-energy plant

23 June 2021 - Novozymes, the world leader in biological solutions, is included as part of ARC´s EU application to set up a carbon capture facility at the Amager Resource Center (ARC) in Copenhagen. Novozymes’ biosolution for enzymatic carbon capture is to be tested as a possible solution for the future carbon capture plant. The captured carbon dioxide (CO2) by project ClimAid Copenhagen will either be utilized or stored. Following a successful application, ARC is set to be operational by 2025. 

“We are seeking to demonstrate the feasibility of enzymatic carbon capture technology. This aligns well with Novozymes’ commitments to innovation and climate action. In 2020, Novozymes enabled savings of 49 million tons of CO2 in global transport, and we hope that carbon capture technology can significantly accelerate the path to achieving global climate goals, together with our customers and partners,” says Amy Byrick, Executive Vice President of Strategy & Business Transformation at Novozymes.


 

A greener green technology

Currently, the majority of solutions for carbon capture are amine-based systems, which require significant amounts of chemicals to be effective, or are high temperature carbonate processes. 

The difference to conventional systems is that the enzymatic solution uses non-toxic & non-corrosive solvents at a lower stripping temperature. This lower temperature enables the use of low value heat and use of hot water instead of hot steam, which saves energy costs. 

As there is no toxic waste generated with the enzyme process, there are no extra costs for wastewater treatment - the wastewater from the process can go directly to ordinary municipal wastewater treatment.

Collaborating to deliver on climate pledges

The EU is aiming to cut GHG emissions by 55% by 2030 and 100% by 2050. This will not be possible without large-scale deployment of carbon capture and the ARC project is an important steppingstone on the way.

Novozymes will, together with Saipem and Babcock & Wilcox, provide a separate tender to ARC in the second half of 2022, in line with industry project infrastructure development practices, to provide the enzymatic carbon capture solution for ARC.

“It is crucial that the private sector invests in the green transition. ARC is pleased that Novozymes has announced its dedication to maturing carbon capture by developing enzyme-accelerated methods to capture CO2,” says Jacob H. Simonsen, Chief Executive Officer at Amager Resource Center. “Developing enzyme-accelerated alternatives to traditional methods of carbon capture will help to build knowledge and can potentially make the process more effective and sustainable, resulting in reduced cost for the green transformation. It is both in the interest of ARC, Denmark and the global climate.”

About Carbon Capture:

Carbon capture and storage (CCS) involves avoiding the release of CO2 emissions into the atmosphere from industrial processes, such as steel and cement production, or from the burning of fuels in power generation. This carbon is then transported from where it was produced, via ship or in a pipeline, and stored deep underground in geological formations. Amine-based technology has been under development since the 1980s and has been proven to be both safe and effective in the US and around the world.

About Novozymes:

Novozymes is the world leader in biological solutions. Together with customers, partners and the global community, Novozymes improves industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bio-innovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

NASDAQ OMX: NZYM-B • 6,500 employees • DKK 14,5 billion turnover • 30+ industries • 700+ products

About Amager Resource Center (ARC):

Amager Resource Center (ARC) is a public company owned by five municipalities in Copenhagen that provides waste management services, electricity, and district heating for 600,000 citizens and 68,000 businesses. 

ARCs business area includes collection of household waste, recycling, a sorting plant and a landfill.

At the world-famous facility, Amager Bakke, visitors can ski or hike on the roof top while the waste-to-energy plant below treats the residual waste of 660,000 inhabitants and 68,000 companies and produces heat and electricity.

About Saipem: 

Saipem is a leading company in engineering, drilling and construction of major projects in the energy and infrastructure sectors. It is “One-Company” organized in five business divisions (Offshore E&C, Onshore E&C, Offshore Drilling, Onshore Drilling and XSIGHT, dedicated to consulting and engineering services in the project definition phase). Saipem is a global solution provider with distinctive skills and competences and high-tech assets, which it uses to identify solutions aimed at satisfying customer requirements. Listed on the Milan Stock Exchange, it is present in over 60 countries worldwide and has 32 thousand employees of 130 different nationalities

About Babcock & Wilcox:

Headquartered in Akron, Ohio, Babcock & Wilcox Enterprises is a leader in energy and environmental products and services for power and industrial markets worldwide. Follow us on LinkedIn and learn more at www.babcock.com.

Get in touch

Media relations

Lina Danstrup

Lina Danstrup

Head of External Communicationlind@novozymes.com+45 30 77 05 52

Related articles

Novonesis HQ in Lyngby, Denmark
01.02.24 | 8 minute read

Legacy Novozymes delivers solid last full-year results

Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality.
Novonesis office
29.01.24 | 6 minute read

The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner

Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for better business, healthier lives, and a healthier planet. The combined company brings together 10,000 people worldwide and an expertise that spans more than 30 different industries. Novonesis is already assisting companies around the world in meeting both business needs and the needs of the planet.
Novonesis
13.12.23 | 8 minute read

Novozymes and Chr. Hansen announce name of future combined company; Novonesis

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. Novozymes and Chr. Hansen have announced that the name of the future combined company will be ‘Novonesis’. Novonesis means ‘A new beginning’ and derives from the Greek word ‘genesis’. The name reflects a new era of biosolutions where innovation in biological sciences and technology will offer solutions to solve some of the biggest challenges facing humanity.